Mutationsanalysen von K-ras und p53 bei Patienten mit Plattenepithelkarzinom des ÖsophagusLisa Holper1.122.2342.1.2.1.1.567623#2812.1.2.89102.1.3.112.1.4.122.1.5.132.1.6.14616#63115616#398616#23716616#445616#3942.1.7.17181920605#9332.2.2.2.1.212.2.2.22624#4682.2.3.232.2.4.2425336#256262.3.2.3.1.272.3.2.28292.3.3.30312.3.4.3.3.1.3132616#8103.2.333.2.1.34353.2.2.36373.2.3.383.2.4.393.3.3.3.1.403.3.2.3.3.3.413.3.4.424344454647483.3.5.493.3.6.50513.3.7.523.3.8.3.3.8.1.533.3.8.2.616#6854.4.1.5354616#8104.2.554.3.624#2624.4.564.5.5758594.5.1.60623#43161623#229623#23062623#46763623#246623#246644.5.2.65623#46766623#46767623#246684.5.3.69705.5.1.705.2.71725.3.735.4.74755.5.7677785.6.79 6. Danksagung 7. LiteraturverzeichnisErklärung an Eides StattLebenslauf 605#933deInhaltsverzeichnisHilfe 7. Literaturverzeichnis

(1) Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, WolffG, Hauptmann S, Dörken B, Daniel P : Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol. 2001, 19(8), S.2272-81.

(2) Casson AG, Wilson SM, McCart JA, O'Malley FP, Ozcelik H, Tsao MS, Chambers AF: ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer. 1997, 72(5), S.739-45.

(3) Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, Buffa R, Ferrero S, Piazza M, Blandamura S, Segalin A, Bonavina L, Peracchia A: p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer. 1997, 79(3), S.425-32.

(4) Cahill DP, Kinzler KW, Vogelstein B, Lengauer C: Genetic instability and darwinian selection in tumours. Trends Cell Biol. 1999, 9(12), S.M57-60.

(5) Kenneth, W., Kinzler, BV.: Lessons from Hereditary Colorectal Cancer. Cell. 1996, 87, S.159-170.

(6) Yang G, Zhang Z, Liao J, Seril D, Wang L, Goldstein S, Yang CS: Immunohistochemical studies on Waf1p21, p16, pRb and p53 in human esophageal carcinomas and neighboring epithelia from a high-risk area in northern China. Int J Cancer. 1997, 72(5), S.746-51.

(7) Tian D, Feng Z, Hanley NM , Setzer RW, Mumford JL, DeMarini DM: Multifocal accumulation of p53 protein in esophageal carcinoma: evidence for field cancerization. Int J Cancer. 1998, 78(5), S.568-75.

(8) Chino O, Makuuchi H, Shimada H, Machimura T, Mitomi T, Osamura RY: Assessment of the proliferative activity of superficial esophageal carcinoma using MIB-1 immunostaining for the Ki-67 antigen. J Surg Oncol. 1998, 67(1), S.18-24.

(9) D´Amico, TA., Harpole, DH.: Molecular biology of esophageal cancer. Chest Surg Clin N Am. 2000, 10(3), S.451-69.

(10) Phillips, DH.: Fifty years of benzo(a)pyrene. Nature. 1983, 303(5917), S.468-72.

(11) Hager G, Formanek M, Gedlicka C, Knerer B, Kornfehl J: Ethanol decreases expression of p21 and increases hyperphosphorylated pRb in cell lines of squamous cell carcinomas of the head and neck. Alcohol Clin Exp Res. 2001, 25(4), S.496-501.

(12) Gaus W, Hingst V, Mattern R u.a.: Ökologisches Stoffgebiet, Duale Reihe. Thieme, MLP: 1999, 3. Auflage.

(13) He D, Zhang DK, Lam KY, Ma L, Ngan HY, Liu SS, Tsao SW: Prevalence of HPV infection in esophageal squamous cell carcinoma in Chinese patients and its relationship to the p53 gene mutation. Int J Cancer. 1997, 72(6), S.959-64.

(14) Vita, d.: Cancer of the Esophagus. 1998.

(15) Huang J, Hu N, Goldstein AM, Emmert-Buck MR, Tang ZZ, Roth MJ, Wang QH, Dawsey SM, Han XY, Ding T, Li G, Giffen C, Taylor PR: High frequency allelic loss on chromosome 17p13.3-p11.1 in esophageal squamous cell carcinomas from a high incidence area in northern China. Carcinogenesis. 2000, 21(11), S.2019-26.

(16) Biramijamal F, Allameh A, Mirbod P, Groene HJ, Koomagi R, Hollstein M: Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran. Cancer Res. 2001, 61(7), S.3119-23.

(17) Kato H, Miyazaki T, Yoshikawa M, Nakajima M, Fukai Y, Tajima K, Masuda N, Tsutsumi S, Tsukada K, Nakajima T, Kuwano H: Nitrotyrosine in esophageal squamous cell carcinoma and relevance to p53 expression. Cancer Lett. 2000, 153(1-2), S.121-7.

(18) Terry P, Lagergren J, Ye W, Nyren O, Wolk A: Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer. 2000, 87(5), S.750-4.

(19) Ralhan R, Arora S, Chattopadhyay TK, Shukla NK, Mathur M: Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India . Int J Cancer. 2000, 85(6), S.791-5.

(20) Fong LY, Lau KM, Huebner K, Magee PN: Induction of esophageal tumors in zinc-deficient rats by single low doses of N-nitrosomethylbenzylamine (NMBA): analysis of cell proliferation, and mutations in H-ras and p53 genes. Carcinogenesis. 1997, 18(8), S.1477-84.

(21) Schlemper RJ, Dawsey SM, Itabashi M, Iwashita A, Kato Y, Koike M, Lewin KJ, Riddell RH, Shimoda T, Sipponen P, Stolte M, Watanabe H: Differences in diagnostic criteria for esophageal squamous cell carcinoma between Japanese and Western pathologists. Cancer. 2000, 88(5), S.996-1006.

(22) Yang HL, Dong YB, Elliott MJ, Liu TJ, McMasters KM: Caspase activation and changes in Bcl-2 family member protein expression associated with E2F-1-mediated apoptosis in human esophageal cancer cells. Clin Cnacer Res. 2000, 6(4), S.1579-89.

(23) Rigberg DA, Kim FS, Blinman TA, Cole MA, Lane JS, So J, McFadden DW: p21 expression is increased by irradiation in esophageal squamous cell carcinoma. J Surg Res. 1998, 76(2), S.137-42.

(24) Kanamoto A, Kato H, Tachimori Y, Watanabe H, Nakanishi Y, Kondo H, Yamaguchi H, Gotoda T, Muro K, Matsumura Y: No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol. 1999, 72(2), S.94-8,

(25) Pisani P, Parkin DM, Bray F, Ferlay J: Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999, 83(6), S.18-29,870-73.

(26) Natsugoe S, Nakashima S, Matsumoto M, Xiangming C, Okumura H, Kijima F, Ishigami S, Takebayashi Y, Baba M, Takao S, Aikou T: Expression of p21WAF1/Cip1 in the p53-dependent pathway is related to prognosis in patients with advanced esophageal carcinoma. Clin Cancer Res. 1999, 5(9), S.2445-9.

(27) Daniel P, Wieder T, Sturm I, Schulze-Osthoff K: The kiss of death: Promises and failures of death receptors and ligands in cancer therapy. Review. Leukemia. 2001, 15(7), S.1022-32.

(28) Klinische Pharmakologie: ein Leitfaden für die Praxis. Hrsg.: Rietbrock, Staib, Loew: 1996.

(29) Wadler S, Haynes H, Beitler JJ, Hu X, Fell S, Camacho M, Levine B, Wiernik PH: Phase II clinical trial with 5-fluorouracil, recombinant interferon- alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. Cancer. 1996, 78(1), S.30-34.

(30) Damle S, Beitler JJ, Haynes H, Camacho M, Wolf E, Wadler S: Phase I-II study of 5-fluorouracil, recombinant interferon alpha2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus. Am J Clin Oncol. 1999, 22(4), S.391-5.

(31) Adham M, Baulieux J, Mornex F, de La Roche de Bransat E, Ducerf C, Souquet JC, Gerard JP: Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus. Cancer. 2000, 89(5), S.946-54.

(32) Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood. 1997, 89(6), S.1845-53.

(33) Lpane D: Cancer. p53, guardian of the genom. Nature. 1992, 358, S.15-26.

(34) Noguchi H, Naomoto Y, Kondo H, Haisa M, Yamatsuji T, Shigemitsu K, Aoki H, Isozaki H, Tanaka N: Evaluation of endoscopic mucosal resection for superficial esophageal carcinoma. Surg Laparosc Endosc Percutan Tech. 2000, 10(6), S.343-50.

(35) Benhidjeb T, Moesta KT, Schlag PM: Staging and neoadjuvant therapy of squamous cell carcinoma of esophagus. Ther Umsch. 2001, 58(3), S.165-73.

(36) Cohen GM: Caspases: the executioners of apoptosis. Biochem J. 1997, 326(Pt 1), S.1-16.

(37) Angelastro JM, Moon NY, Liu DX, Yang AS, Greene LA, Franke TF: Characterization of a novel isoform of caspase-9 that inhibits apoptosis. J Biol Chem. 2001, 276(15), S.12190-200.

(38) Cain K, Bratton SB, Langlais C, Walker G, Brown DG, Sun XM, Cohen GM: Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes. J Biol Chem. 2000, 275(9), S.6067-70.

(39) Azmi S, Dinda AK , Chopra P, Chattopadhyay TK, Singh N: Bcl-2 expression is correlated with low apoptotic index and associated with histopathological grading in esophageal squamous cell carcinomas. Tumour Biol. 2000, 21(1), S.3-10.

(40) Bos JL: Ras Oncogenes in human cancer: a review. Cancer Res. 1989, 49, S.4682-89.

(41) Valencia A, Chardin P, Wittinghofer A, Sander C: The ras protein familiy: evolutionary tree and role of conserved amino acids. Biochem. 1991, 30, S.4637-48.

(42) Maher J, Baker DA, Manning M, Dibb NJ , Roberts IA: Evidience for cell-specific differences in transformation by N-, H- and K-ras. Oncogene. 1995, 11: 1639-47

(43) McCormick F: Signal transduction. How receptors turn ras on. Nature. 1993, 36. 315-16.

(44) Bos JL: P21 ras: an oncoprotein functioning in growth factor-induced signal transduction. Eur J Cancer. 1995. 31A : 1051-54.

(45) de Vries JE, ten Kate J, Bosman FT : P21ras in carcinogenesis. Pathol Res Pract. 1996, 6: 58-68.

(46) Grand RJ, Owen D: The biochemistry of ras p21. Biochem J. 1991, 60: 9-31.

(48) Arber N, Shapira I, Ratan J, Stern B, Hibshoosh H, Moshkowitz M, Gammon M, Fabian I, Halpern Z: Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology. 2000, 118(6): 1045-50.

(49) Keohavong, P., Gao, WM., Siegfried, JM., Luketich, JD., Melhem, MF. Topographic analysis of K-ras mutations in histologically normal lung. Br J Cancer. 2001, 85(2): 235-41.

(50) Miyashita, T., Reed, JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995, 80(2): 293-9. (51) Kobayashi S, Koide Y, Endo M, Isono K, Ochiai T: The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability. Am J Surg. 1999, 177(6): 497-502.

(52) Gartel AL, Serfas MS, Gartel M, Goufman E, Wu GS, el-Deiry WS, Tyner AL: p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. Exp Cell Res. 1996, 227(2): 171-81.

(53) Yang G, Zhang Z, Liao J, Seril D, Wang L, Goldstein S, Yang CS: Immunohistochemical studies on Waf1p21, p16, pRb and p53 in human esophageal carcinomas and neighboring epithelia from a high-risk area in northern China. Int J Cancer. 1997, 72(5): 746-51.

(54) Bos JL: Ras Oncogenes in human cancer: a review. Cancer Res. 1989, 49: 4682-89.

(55) Capella G, Cronauer-Mitra S, Pienado MA, Perucho M: Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect. 1991, 93: 125-31.

(56) Kahn SM, Jiang W, Culbertson TA, Weinstein IB, Williams GM, Tomita N, Ronai Z: Rapid and sensitive nonradioactive detection of mutant K-ras genes via "enriched" PCR amplification. Oncogene. 1991, 6: 1079-83.

(57) Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C, Marshall CJ: Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res. 1991, 51: 3497-3502.

(58) Shi ST, Yang GY, Wang LD, Xue Z, Feng B, Ding W, Xing EP, Yang CS: Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. Carcinogenesis. 1999, 20(4): 591-7.

(60) Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T: Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000, 89(8): 1677-83.

(61) Hagiwara N, Onda M, Miyashita M, Sasajima K: Detection of Circulating Anti-p53 Antibodies in Esophageal Cancer Patients. J Nippon Med Sch. 2000, 67(2) :110-117.

(62) Crisan D, Mattson JC: Retrospective DNA analysis using fixed tissue specimens. DNA Cell Biol. 1993, 12(5): 455-64.

(63) Newton, CR.: PCR, 1994

(64) Janice, A., Bourne, D.Handbuch der Immunperoxidase Färbemethoden.

(65) Lord RV, O'Grady R, Sheehan C, Field AF, Ward RL: ras codon 12 mutations in Barrett´s oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroenterol Hepatol. 2000, 15(7): 730-6.

(66) Galiana C, Lozano JC, Bancel B, Nakazawa H, Yamasaki H: High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. Mol Carcinog. 1995, 14(4): 286-93.

(67) Barch DH, Jacoby RF, Brasitus TA, Radosevich JA, Carney WP, Iannaccone PM: Incidence of Harvey ras oncogene point mutations and their expression in methylbenzylnitrosamine-induced esophageal tumorigenesis. Carcinogenesis. 1991, 12(12): 2373-7.

(68) Levine AJ: p53, the cellular gatekeeper for growth and division. Cell. 1997, 88: 323-31.

(69) Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998, 282: 1497-501.

(70) Ribeiro U Jr, Finkelstein SD , Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, Swalsky PA, Gooding WE, Posner MC: p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer. 1998, 83(1): 7-18.

(71) Lam KY, Tsao SW, Zhang D, Law S, He D, Ma L, Wong J: Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinoma: a prospective clinico-pathological study and survival analysis of 70 patientsInt. J Cancer. 1997, 74: 212-19.

(72) Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC: Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA. 1990, 879: 958-61.

(73) Wagata T, Shibagaki I, Imamura M, Shimada Y, Toguchida J, Yandell DW, Ikenaga M, Tobe T, Ishizaki K: Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res. 1993, 53: 846-50.

(74) Ikeda G, Isaji S, Chandra B, Watanabe M, Kawarada Y: Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer. 1999, 86(8): 1396-405.

(75) Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert HE: Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res. 1998, 4(12): 2991-7.

(76) Itoshima T, Fujiwara T, Waku T, Shao J, Kataoka M, Yarbrough WG, Liu TJ, Roth JA, Tanaka N, Kodama M: Induction of apoptosis in human esophageal cancer cells by sequential transfer of the Wildtype p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation. Clin Cancer Res. 2000, 6(7): 2851-9.

(77) Ikeguchi M, Saito H, Katano K, Kondou A, Tsujitani S, Maeta M, Kaibara N: Radiochemosensitivity and expression of p53 in patients with esophageal cancer treated by absolute noncurative resection. Anticancer Res. 1998, 18(1B): 493-7.

(78) Sturm I, Bosanquet AG, Hermann S, Guner D, Dörken B, Daniel PT: Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DANN-damaging chemotherapy. Cell Death and Differentiation. 2003, 10: 477-84.

(79) Daniel P, Sturm I, Hemmati PG, Güner D: Pharmakogenomik maligner Tumoren: Bedeutung von Zellzyklus- und Apoptosedefekten für Therapieansprechen und Krankheitsprognose. Onkologe. 2004, 10: 46-54.

(80) Schelwies K, Sturm I, Grabowski P, Scherubl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO, Zeitz M, Dörken B, Daniel PT: Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer. 2002, 99: 589-96.

(81) Daniel P: Zellzyklus und Apoptose: Molekulare Grundlagen von hämatologischen Neoplasien. Springer-Verlag Berlin Heidelberg. 2003.

(82) Beaupre DM, Kurzrock R: RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol. 1999, 17: 1071-79.

(83) Kuida K: Caspase-9. Int J Biochem Cell Biol. 2000, 32(2): 121-4.

(84) Earnshaw WC, Martins LM, Kaufmann SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999, 68: 383-424.

(85) Gamieldien W, Victor TC, Mugwanya D, Stepien A, Gelderblom WC, Marasas WF, Geiger DH, van Helden PD: p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa. Int J Cancer. 1998, 78(5 ): 544-9.

(86) Tolbert DM, Noffsinger AE, Miller MA, DeVoe GW, Stemmermann GN, Macdonald JS, Fenoglio-Preiser CM: p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Mod Pathol. 1999, 12(1): 54-60.

(87) Tumor Zentrum Berlin e.V., Robert-Koch-Platz 1, 10115 Berlin: Leitlinien für Ösophaguskarzinom

(88) Informationszentrum für Standards in der Onkologie (ISTO), Deutsche Krebsgesellschaft e.V., Kurzgefasste Interdisziplinäre Leitlinien 2002 für Ösophaguskarzinom

(89) Tumorzentrum Freiburg, Klinikum der Albert-Ludwigs-Universität. Empfehlungen zur standardisierten Diagnostik, Therapie und Nachsorge des Ösophaguskarzinoms. 2001.

(90) Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B, Daniel PT: Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999, 17(5): 1364-74.

(91 ) Sturm I, Bosanquet AG, Hermann S, Güner D, Dörken B, Dankiel PT: Mutation of p53 an consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA damging chemotherapy. Cell Death Differ. 2003, 10: 477-484.

(92) Bosanquet AG, Sturm I, Wieder T, Essmann F, Bosanquet MI, Head DJ, Dörken B, Daniel PT: Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but nor fludarabin, dadribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia. 2002, 16: 1035-1044.

(93) Blagosklonny MV: Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene. 2002, 21: 6249-6254.

(94) Gaducci A, Ciani C, Cosio S, Carnino F, Fanucchi A, Buttitta F, Conte PF, Genazzani AR : p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paditaxel-based regimen. Anticancer Res. 2000, 20: 4793-4799.

(95) Sjostrom J, Blomqvist C, Heikkila P, Boguslawski KV, Raisanen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstadt B, Bergh J, Wist E, Valvere V, Saksela E: Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res. 2000, 6: 3103-3110.

(96) Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlbock M, Gnant M, Steger G, Jakesz R T: P53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin cancer Res. 2000, 6: 50-56.

(97) Mrozek A, Petrowsky H, Sturm I, Kraus J, Hermann S, Hauptmann S, Lorenz M, Dörken B, Daniel PT: Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability. Cell Death Differ. 2003, 10(4): 461-7. (98) Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess H, Schlag PM, Dörken B, Daniel PT: Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol. 2003, 21(18): 3391-401.